BNT162 Vaccine Description
BioNTech’s BNT162 vaccine candidates are being developed to prevent COVID-19 disease infection. The BNT162 program is evaluating at least 4 experimental vaccines, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen.
BNT162b1 and BNT162b2 are both nucleoside-modified RNAs, formulated in lipid nanoparticles.
BNT162b1 encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen, while BNT162b2 encodes an optimized SARS-CoV-2 full-length spike protein antigen.
In an ongoing Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate expressing the SARS-CoV-2 receptor-binding domain (RBD) is being evaluated in 45 subjects. This study was last updated on June 29, 2020.
Two of the 4 vaccine candidates include a nucleoside modified mRNA (modRNA), one includes a uridine containing mRNA (uRNA), and the fourth vaccine candidate utilizes self-amplifying mRNA (saRNA). Each mRNA format is combined with a lipid nanoparticle (LNP) formulation.
The larger spike sequence is included in two of the vaccine candidates, and the smaller optimized RBD from the spike protein is included in the other 2 vaccine candidates.
The RBD-based candidates contain the piece of the spike that is thought to be most important for eliciting antibodies that can inactivate the virus.
On July 1, 2020, the manuscript describing the preliminary clinical data for BNT162b1 is available online and is concurrently undergoing scientific peer-review for potential publication.
The Project Lightspeed vaccine development program is based on BioNTech’s proprietary mRNA-based technology platforms and supported by Pfizer’s global vaccine development capabilities.
On July 27, 2020, the Companies advance nucleoside-modRNA candidate BNT162b2, which encodes an optimized SARS-CoV-2 full-length spike glycoprotein, at a 30µg dose level, in a 2-dose regimen, into Phase 2/3 study of up to 30,000 participants aged 18 – 85 years, and is expected to include approximately 120 sites globally.
And on July 31, 2020, the companies agreed to supply 120 million vaccine doses to Japan in the first half of 2021, subject to regulatory approval.
In anticipation of a successful clinical development program, Pfizer plans to activate its extensive manufacturing network and invest at risk in an effort to produce an approved COVID-19 vaccine as quickly as possible for those most in need around the world.
In case the safety and efficacy study is successful, and the vaccine receives regulatory approval, the companies are expecting to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.3 billion vaccine doses by the end of 2021
During the clinical development stage, BioNTech will provide its partners clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
BioNTech is also collaborating with Fosun Pharma to develop BNT162 in China, where the companies expect to conduct trials.
Biopharmaceutical New Technologies is an immunotherapy company pioneering novel therapies for cancer and other serious diseases.
BNT162 Vaccine Indication
BNT162 is a vaccine candidate that intends to prevent the SARS-CoV-2 coronavirus from causing COVID-19 disease in humans.
Overall, the preliminary data demonstrated that BNT162b1 could be administered in a dose that was well tolerated and generated dose-dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers.
BNT162 Vaccine Dosage
The dose-escalation portion of the Phase 1/2 trials will include approximately 360 healthy subjects between the ages of 18 to 55. The study consists of 3 stages. Stage 1: to identify preferred vaccine candidate(s), dose level(s), number of doses, and schedule of administration (with the first 15 participants at each dose level of each vaccine candidate comprising a sentinel cohort); Stage 2: an expanded-cohort stage; and Stage 3; a final candidate/dose large-scale stage.
At day 28 (7 days after dose 2), all subjects who received 10 or 30 µg of BNT162b1 had significantly elevated RBD-binding IgG antibodies with geometric mean concentrations (GMCs) of 4,813 and 27,872 units/ml which are 8- and 46.3-times, respectively, the GMC of 602 units/ml in a panel of 38 sera of convalescent patients who had contracted SARS-CoV-2.
On day 28 (7 days after dose 2), all subjects who received 10 or 30 µg of BNT162b1 had SARS-CoV-2 neutralizing antibodies with geometric mean titers (GMTs) of 168 and 267, which are 1.8- and 2.8-times, respectively, the GMT of the convalescent serum panel.
Local reactions and systemic events after immunization with 10 µg and 30 µg of BNT162b1 were dose-dependent, generally mild to moderate, and transient. No serious adverse events were reported.
These studies will also evaluate the effects of repeated immunization for three of the 4 vaccine candidates which utilize uRNA or modRNA.
Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. And, subjects with a higher risk for a severe COVID-19 infection will be included in the second part of the study.
BNT162 Vaccine News
August 5, 2020 - Pfizer Canada and BioNTech SE announced an agreement with the Government of Canada to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and Health Canada approval.
July 31, 2020 - Pfizer and BioNTech SE announced an agreement with the Ministry of Health, Labour, and Welfare in Japan to supply 120 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, beginning in 2021.
July 27, 2020 - Pfizer Inc. and BioNTech SE announced the start of a global, except for China, Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2.
July 22, 2020 - Pfizer and BioNTech SE announced the execution of an agreement with the U.S. government to meet Operation Warp Speed program's goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine after Pfizer successfully manufactures and obtains approval or emergency use authorization from the US Food and Drug Administration. The government also has an option to acquire an additional 500 million doses of BNT162.
July 20, 2020 - Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, which is currently in development.
July 13, 2020 - Pfizer Inc. and BioNTech SE announced that 2 of the companies’ 4 investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) received Fast Track designation from the U.S. FDA. These vaccine candidates in the BNT162 program are currently being evaluated in ongoing Phase 1/2 clinical studies in the USA and Germany.
July 10, 2020 - BioNTech Chief Executive Officer Ugur Sahin predicted the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.
July 9, 2020 - A Maryland-based graduate immunology student believes he could be one of the 1st people in the USA to produced coronavirus antibodies in response to being vaccinated in phase 2 clinical trial conducted at the University of Maryland.
July 1, 2020 - Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with the dose level and after a second dose. Geometric mean neutralizing titers reached 1.8- to 2.8-fold that of a panel of COVID-19 convalescent human sera.
June 29, 2020 - BioNTech SE announced a private investment of USD 250 million by investors.
June 24, 2020 - Cincinnati Children’s vaccine program is one of 4 sites testing for the BNT162 vaccine. It's continuing to enroll participants in the first stage of the study and wants underrepresented populations.
May 30, 2020 - Global pharmaceutical Pfizer CEO Albert Bourla said he believes that a vaccine could be available in the fall of 2020.
May 13, 2020 - SARS‐CoV‐2 immunogenicity at the crossroads. Letter to the editor.
May 12, 2020 - Pfizer CEO and Chairman Albert Bourla told CNBC hat the company plans to expand human trials of its experimental coronavirus vaccine to thousands of test patients by September 2020. Pfizer is currently testing four different vaccine variations, Bourla said during CNBC’s Healthy Returns Virtual Summit. If one or two variations indicate success, the company will ramp up trials, and then in September launch a broad large-scale study with thousands of participants if a vaccine proves to be successful.
May 5, 2020 - Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
April 29, 2020 - BioNTech SE and Pfizer Inc. announced that the first cohort of BioNTech’s Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020.
April 28, 2020 - Pfizer's CEO said the company expects to make safety data available by late May 2020 and move into expanded trials that could allow emergency use or accelerated approval starting in the fall.
April 22, 2020 - Pfizer Inc. and BioNTech SE have entered into a global collaboration agreement to co-develop BioNTech’s potential first-in-class, mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection. The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple research sites. The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020 subject to the technical success of the development program and approval of regulatory authorities and then rapidly scale up to the capacity to produce hundreds of millions of doses in 2021.
April 9, 2020 - BioNTech SE and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.
March 17, 2020 - BioNTech announced details of its efforts to develop a potential vaccine to induce immunity and prevent COVID-19 infection. BioNTech is working to initiate clinical testing for BNT162, a potential first-in-class mRNA vaccine against COVID-19, in late April 2020.
March 16, 2020 - BioNTech also announced a strategic alliance with Fosun Pharma to develop its COVID-19 vaccine in China. Under the terms of the agreement, the two companies will work together on the development of BNT162 in China, conducting clinical trials in China and leveraging Fosun Pharma’s extensive clinical development, regulatory, and commercial capabilities in the country. If approved, Fosun Pharma will commercialize the vaccine in China.
BNT162 Vaccine Clinical Trials
Clinical Trial NCT04368728: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS - Last Update Posted: July 23, 2020.
Pfizer and BioNTech finalized the Phase 2/3 study protocol in response to feedback from global regulators, including the FDA and the German Paul-Ehrlich-Institut. The Phase 2/3 study is an event-driven trial that is planned to enroll up to 30,000 participants between 18 and 85 years of age.
The Phase 2/3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The trial’s primary endpoints will be the prevention of COVID-19 in those who have not been infected by SARS-CoV-2 prior to immunization, and prevention of COVID-19 regardless of whether participants have previously been infected by SARS-CoV-2.
Secondary endpoints include the prevention of severe COVID-19 in those groups. The study also will explore the prevention of infection by SARS-CoV-2, the virus that causes COVID-19. The primary efficacy analysis will be an event-driven analysis based on the number of participants with symptomatic COVID-19 disease. The trial design allows for interim analyses and unblinded reviews by an independent external Data Monitoring Committee.
Clinical Trial NCT04368728 - Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults - Last updated on June 29, 2020.
- This is a Phase 1/2, randomized, placebo-controlled, observer-blind, dose-finding, and vaccine candidate-selection study in healthy adults.
- The study will evaluate the safety, tolerability, immunogenicity, and potential efficacy of up to 4 different SARS-CoV-2 RNA vaccine candidates against COVID-19:
- As a 2-dose or single-dose schedule
- At up to 3 different dose levels
- The manuscript describing the preliminary clinical data for the nucleoside-modified messenger RNA candidate, BNT162b1, which encodes an optimized SARS-CoV-2 RBD antigen, is available on an online and is concurrently undergoing scientific peer-review for potential publication.
BNT162 Europe (2020-001038-36) - The first cohort of BioNTech’s Phase 1/2 clinical trial was dosed. BNT162 is the first COVID-19 vaccine candidate in Europe which entered clinical trials. Twelve study participants were dosed with the first BNT162 vaccine candidate as of April 29th. The dose-escalation portion of the Phase 1/2 trial will include approximately 200 healthy subjects between the ages of 18 to 55 and will target a dose range of 1 µg to 100 µg, aiming to determine the optimal dose for further studies as well as to evaluate the safety and immunogenicity of the vaccine. The three vaccine candidates that utilize uRNA or modRNA will be administered as two injections. The fourth vaccine candidate, which contains saRNA, will be evaluated after a single dose of vaccine. Subjects with a higher risk of severe COVID-19 disease will be included in the second part of the study. The first clinical data from the trial is expected end of June or in July 2020.
BNT162 (U.S) – The first cohort has been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program. The Phase 1/2 study is designed to determine the safety, immunogenicity, and optimal dose level of the four mRNA vaccine candidates. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age) and will be seamlessly followed by a part in which the selected vaccine candidate will be administered to several thousands of subjects. The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age.